GT Biopharma (GTBP) Insider Trading & Ownership $2.33 -0.12 (-4.90%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$2.42 +0.09 (+4.03%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GT Biopharma (NASDAQ:GTBP) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.90%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$49,980.00Number OfInsiders Selling(Last 3 Years)0 Get GTBP Insider Trade Alerts Want to know when executives and insiders are buying or selling GT Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GTBP Insider Buying and Selling by Quarter GT Biopharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/11/2023Michael Martin BreenCEOBuy1,666$15.00$24,990.00 4/6/2023Manu OhriCFOBuy1,666$15.00$24,990.00 (Data available from 1/1/2013 forward) GTBP Insider Trading Activity - Frequently Asked Questions Who is on GT Biopharma's Insider Roster? The list of insiders at GT Biopharma includes Manu Ohri, and Michael Martin Breen. Learn more on insiders at GTBP. What percentage of GT Biopharma stock is owned by insiders? 10.90% of GT Biopharma stock is owned by insiders. Learn more on GTBP's insider holdings. GT Biopharma Key ExecutivesMr. Michael Martin Breen (Age 61)Interim CEO & Executive Chairman Compensation: $1.04MMr. Manu Ohri (Age 69)CFO & Secretary Compensation: $647.07kDr. Jeffrey S. Miller M.D.Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific Advisor More Insider Trading Tools from MarketBeat Related Companies CYTH Insider Transactions CDIO Insider Transactions KALA Insider Transactions VYNE Insider Transactions MTEX Insider Transactions LEXX Insider Transactions ELEV Insider Transactions QTTB Insider Transactions LIAN Insider Transactions PASG Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles McDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why This page (NASDAQ:GTBP) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GTBP Stock Free GTBP Stock Alerts